FDA Investigates Lead in Cinnamon Applesauce

202-434-4100

Litigation Attorney / Real Estate and Commercial Litigator
On Balance Search Consultants

Trusts & Estates Attorney / Estate Planning Lawyer
On Balance Search Consultants

Matrimonial Attorney
On Balance Search Consultants

Litigation Paralegal
Greenberg Traurig

Trusts & Estates Partner / Senior Attorney
On Balance Search Consultants

Family/Matrimonial Law Attorney
On Balance Search Consultants

Litigation Legal Support Specialist
Greenberg Traurig

Chief Operating Officer / Business Manager
On Balance Search Consultants

Legal Expert in Commercial & Real Estate Litigation / Property Dispute Speciali…
On Balance Search Consultants

Commercial Real Estate Transactional Attorney / Real Estate Lawyer
On Balance Search Consultants

Investigation Into Lead-Contaminated Applesauce Continues

Tuesday, December 19, 2023

Print Mail Download info_icon_img

FDA is continuing to investigate the elevated lead levels in cinnamon used in applesauce pouches that were recalled beginning October 31, 2023. Most recently, inspectors collected samples that the cinnamon supplier sold to the applesauce manufacturer, finding extremely high levels of lead contamination at 5,110 parts per million (ppm) and 2,270 ppm. For context, the Codex Alimentarius Commission is considering adopting 2.5 ppm as the maximum level for lead in cinnamon, among other similar spices.
To date, there have been approximately 65 reported cases of children displaying symptoms of lead toxicity related to the applesauce pouches. FDA has not found evidence that any other products, including pouches from the same brands that do not contain cinnamon, are related to the recall. The pouches implicated in the recall have been traced back to a manufacturer and cinnamon supplier in Ecuador, and FDA is working closely with Ecuadorian officials who are conducting their own investigation.
FDA has theorized that lead may have been intentionally added to the cinnamon in a case of economic adulteration. Nevertheless, FDA is continuing its investigation and has provided a timeline that it will continue to update as the investigation progresses.